Tekla Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Tekla Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,528	Closed	-$452K	–	189
2018 Q1	$452K	Buy	+1,528	New	+$451K	0.02%	174
2017 Q4	–	Sell	-1,034	Closed	-$341K	–	164
2017 Q3	$341K	Buy	+1,034	New	+$282K	0.01%	148
2015 Q1	–	Sell	-1,348	Closed	-$11.8M	–	124
2014 Q4	$11.8M	Sell	1,348 -809	-38%	-$4.7M	0.55%	42
2014 Q3	$9.64M	Hold	2,157	–	–	0.45%	44
2014 Q2	$13.2M	Hold	2,157	–	–	1.21%	21
2014 Q1	$9.83M	Buy	+2,157	New	+$10.2M	0.98%	27

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tekla Capital Management's EIGR Position: Q2 2018 in Review

Tekla Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2018, closing a stake of 1,528 shares — an estimated $452K sold.

Tekla Capital Management first reported a position in EIGR in Q1 2014 and held it in 6 quarters. The position peaked at $13.2M in Q2 2014. 50 funds tracked by Wall St. Rank hold EIGR as of Q2 2018.

Tekla Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Tekla Capital Management sold 1,528 Eiger BioPharmaceuticals, Inc. shares in Q2 2018, an estimated $452K.
Tekla Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 6 quarters.
Tekla Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $13.2M in Q2 2014.
50 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2018.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.